Biotech Blog

I’m honored to have been selected as one of the judges of the 2010 Biotech Humanitarian award. More details are available in a press release and blog post about the award.  The Biotechnology Industry Association created the Award to recognize an everyday hero who has helped to heal, fuel and feed the planet through their work [...]

The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 1

Time for a new business model? (free full-text)
Yali Friedman
Why data exclusivity is the new patent protection
Peter Pitts
Follow-on biologic drug competition – No need for new marketing exclusivities
Michael S [...]

Drug Patent Expirations in January 2010
*Drugs may be covered by multiple patents

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

XOPENEX
Sepracor
levalbuterol hydrochloride
6,083,993
Jan 5, 2010

XOPENEX HFA
Sepracor
levalbuterol tartrate
5,844,002
Jan 5, 2010

XOPENEX
Sepracor
levalbuterol hydrochloride
5,844,002
Jan 5, 2010

XOPENEX HFA
Sepracor
levalbuterol tartrate
5,760,090
Jan 5, 2010

XOPENEX HFA
Sepracor
levalbuterol tartrate
6,083,993
Jan 5, 2010

XOPENEX
Sepracor
levalbuterol hydrochloride
5,760,090
Jan 5, 2010

MONOPRIL
Bristol Myers Squibb
fosinopril sodium
5,006,344*PED
Jan 10, 2010

MONOPRIL-HCT
Bristol Myers Squibb
fosinopril sodium; hydrochlorothiazide
5,006,344*PED
Jan 10, 2010

CLARINEX
Schering
desloratadine
5,178,878
Jan 12, 2010

REMERON SOLTAB
Organon Usa Inc
mirtazapine
5,178,878
Jan 12, 2010

ORAPRED [...]

This is a guest post from Cliff Cramer, Director of the Healthcare and Pharmaceutical Management Program at Columbia Business School. Do you have a response to Cramer’s post? Post them in the comments section below.

Multi-national pharmaceutical and medical technology companies will increase their investments in emerging markets, notably China and India, to access cost [...]

This is a guest post from BiotechBlog reader Viren Konde. Do you have a response to Viren’s post? If so, you may respond in the comments section below.
The recent editorial on “Intellectual property and biotechnology innovation: To protect or not protect” by Dr Yali Friedman, Managing Editor of the Journal of Commercial Biotechnology was thought [...]

Drug Patent Expirations for December 2009

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

MIGRANAL
Valeant
dihydroergotamine mesylate
5,169,849
Dec 8, 2009

PHOTOFRIN
Axcan Scandipharm
porfimer sodium
5,145,863
Dec 15, 2009

XENICAL
Hoffmann La Roche
orlistat
4,598,089*PED
Dec 18, 2009

CEDAX
Sciele Pharma Inc
ceftibuten dihydrate
4,812,561
Dec 20, 2009

OXILAN-300
Guerbet
ioxilan
4,954,348
Dec 21, 2009

OXILAN-350
Guerbet
ioxilan
4,954,348
Dec 21, 2009

DEFINITY
Lantheus Medcl
perflutren
6,146,657
Dec 22, 2009

ZANTAC 150
Glaxosmithkline
ranitidine hydrochloride
5,102,665*PED
Dec 23, 2009

VALTREX
Glaxosmithkline
valacyclovir hydrochloride
4,957,924*PED
Dec 23, 2009

ZIAGEN
Glaxosmithkline
abacavir sulfate
5,089,500*PED
Dec 26, 2009

TRIZIVIR
Glaxosmithkline
abacavir sulfate; lamivudine; zidovudine
5,089,500*PED
Dec 26, 2009

EPZICOM
Smithkline Beecham
abacavir sulfate; lamivudine
5,089,500*PED
Dec 26, 2009

CORVERT
Pharmacia And Upjohn
ibutilide [...]

This is my initial response to the Kyoto Prize, which I was able to attend on a fellowship from Point Loma Nazarene University. For more details on the Kyoto Prize see my previous post.
I had an opportunity to interact with each of the laureates, and focused on the question of how it was that they [...]

At a recent event on the comparative advantages of small molecule vs. biologic drugs, several themes emerged which led me to re-examine the question of whether the practice of medicine is capable of keeping pace with medical innovation.
As mentioned in a previous post, the majority of patients receiving the personalized medicine drug Herceptin had not [...]

Drug Patent Expirations for November 2009

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

ACULAR LS
Allergan
ketorolac tromethamine
5,110,493*PED
Nov 5, 2009

ACULAR
Allergan
ketorolac tromethamine
5,110,493*PED
Nov 5, 2009

PREVPAC
Takeda Pharms Na
amoxicillin; clarithromycin; lansoprazole
4,628,098*PED
Nov 10, 2009

PREVACID IV
Takeda Pharms Na
lansoprazole
4,628,098*PED
Nov 10, 2009

ACEON
Solvay Pharms
perindopril erbumine
5,162,362
Nov 10, 2009

PREVACID
Takeda Pharms Na
lansoprazole
4,628,098*PED
Nov 10, 2009

PREVACID NAPRAPAC 500 (COPACKAGED)
Takeda Pharms Na
lansoprazole; naproxen
4,628,098*PED
Nov 10, 2009

CARDENE
Ekr Therap
nicardipine hydrochloride
5,164,405
Nov 17, 2009

TROVAN PRESERVATIVE FREE
Pfizer
alatrofloxacin mesylate
5,164,402
Nov 17, 2009

RESCULA
R Tech Ueno [...]

With the issue of data exclusivity for novel biologics re-emerging in the news, I’d like to present two arguments that will be published in the upcoming issue of the Journal of Commercial Biotechnology:
Why data exclusivity is the new patent protection
Peter J Pitts, Center for medicine in the public interest
Follow-on biologic drug competition – No [...]